EU Takes Focused Approach In Bid To Deliver Decentralized Clinical Trials Guide By Year End

EU regulators are eager to roll out harmonized requirements for decentralized clinical trials by the end of 2022 and so have decided to tackle some of the notably trickier issues in greater detail later on.

Digital Clinical Trial
EU Regulators Are Keen To Support Decentralized Clinical Trials • Source: Shutterstock/Alfa Photo

The scope of the highly anticipated pan-EU recommendation paper on decentralized clinical trials (DCTs) is being restricted for now to ensure that the first iteration of the document can be published by the end of this year.

The paper was initially due in the first quarter of 2022, but its publication was pushed back due to the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Clinical Trials

Canada Cuts Red Tape With Single Ethics Review For Trials

A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.

Diversity Action Plans: What To Submit And When

 
• By 

With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.

India Tightens Oversight Of CROs With Mandatory Registration

 
• By 

Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

UK Expedites Cost Negotiations For Companies Conducting ATMP & Early Phase Trials

 

Companies dealing with commercial costings or contracts with the National Health Service for early phase clinical trials or trials of advanced therapy medicinal products should soon be able to conclude their negotiations more quickly.

More from R&D

India Tightens Oversight Of CROs With Mandatory Registration

 
• By 

Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

 
• By 

The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

How To Decarbonize Pharma R&D

 

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.